0
Clinical Investigations in Critical Care |

High-Frequency Oscillatory Ventilation in Adults*: The Toronto Experience

Sangeeta Mehta, MD; John Granton, MD, FCCP; Rod J. MacDonald, RRCP; Dennis Bowman, BSc; Andrea Matte-Martyn, RRT; Thomas Bachman, MSHA; Terry Smith, MD; Thomas E. Stewart, MD, FCCP
Author and Funding Information

*From the Mount Sinai Hospital (Drs. Mehta and Stewart, and Mssrs. MacDonald and Bowman), Toronto; the University Health Network (Dr. Granton and Ms. Matte-Martyn), Toronto; Sunnybrook and Womens’ College Health Sciences Center (Dr. Smith), University of Toronto, Toronto, ON, Canada; and California State University (Mr. Bachman), San Bernardino, CA.

Correspondence to: Sangeeta Mehta, MD, Mount Sinai Hospital, 600 University Ave, No. 1818, Toronto, ON, Canada, M5G 1X5; e-mail: geeta.mehta@utoronto.ca



Chest. 2004;126(2):518-527. doi:10.1378/chest.126.2.518
Text Size: A A A
Published online

Study objectives: To review the clinical experience with high-frequency oscillatory ventilation (HFOV) in three medical-surgical ICUs in Toronto, ON, Canada, and to describe patient characteristics, HFOV strategies, and outcomes.

Design and patients: Retrospective chart review of all patients treated with HFOV at three academic university-affiliated ICUs since 1998. The data extracted included patient demographics, etiology of respiratory failure, ventilator settings, and gas exchange and cardiovascular data from baseline to 72 h of treatment, as well as at the transition from HFOV to conventional ventilation (CV). Heart rate and BP were recorded at regular intervals in all patients, and hemodynamic data were recorded in 32 patients who had pulmonary artery catheters in place. Cointerventions and ICU mortality were also recorded.

Measurements and results: A total of 156 adults (67 women and 89 men; mean [± SD] age, 48 ± 18 years; mean acute physiology and chronic health evaluation [APACHE] II score, 23.8 ± 7.5) with severe ARDS (ie, mean Pao2/fraction of inspired oxygen [Fio2] ratio, 91 ± 48 mm Hg; mean oxygenation index [OI], 31 ± 14) who had received CV for a duration of 5.6 ± 7.6 days underwent 171 trials of HFOV. HFOV was discontinued within 4 h in 19 patients (12%) because of difficulties with oxygenation, ventilation, or hemodynamics. Pao2/Fio2 ratios and OI ([Fio2 × mean airway pressure × 100]/Pao2) improved significantly with the application of HFOV, and this benefit persisted for the 72-h study duration. Significant changes in hemodynamics following HFOV initiation included an increase in central venous pressure and a reduction in cardiac output (throughout the 72 h), and an increase in pulmonary artery occlusion pressure (at 3 and 6 h). Patients were treated with HFOV for 5.1 ± 6.3 days. The 30-day mortality rate was 61.7%. Pneumothorax occurred in 21.8% of patients, 43.6% of patients were treated with inhaled nitric oxide, and 37.2% of patients were treated with steroids. Independent predictors of mortality on multivariate analysis were older age, higher APACHE II score, lower pH at the initiation of HFOV, and a greater number of days receiving CV prior to HFOV.

Conclusions: HFOV has beneficial effects on Pao2/Fio2 ratios and OI, and may be an effective rescue therapy for adults with severe oxygenation failure. The early institution of HFOV may be advantageous.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543